12:00 AM
 | 
Oct 03, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Afluria Quadrivalent: Phase III data

CSL’s Seqirus unit reported data from a double-blind, U.S. Phase III trial in 3,484 adults ages >=18 showing that intramuscular Afluria Quadrivalent met the primary endpoint of non-inferiority to Afluria trivalent influenza vaccine and a trivalent influenza vaccine containing an alternate B strain as...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >